Figure 3.

Safety assessments. (A) Patients treated with sorafenib during the double-blind treatment period and those treated with sorafenib who experience PD before completing 8 cycles and are unblinded (open-label treatment period). (B) Patients who received placebo during the double-blind treatment period and then crossed over to sorafenib after unblinding.

Brose et al. BMC Cancer 2011 11:349   doi:10.1186/1471-2407-11-349
Download authors' original image